Deals
Synergy Pharma Said to Consider Sale Ahead of Trial Results
This article is for subscribers only.
Synergy Pharmaceuticals Inc., a U.S. developer of drugs for gastrointestinal disorders, is talking to advisers about a potential sale of the company, according to people with knowledge of the matter. The shares jumped.
Synergy, which also has $200 million in debt, is exploring a sale after competitor Salix Pharmaceuticals Ltd. agreed to be acquired earlier this month, one of the people said, asking not to be identified as the deliberations are private.